Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00687453 · ClinicalTrials.gov registry record · Phase 4
Insulin Glargine Versus Twice-Daily NPH
A Phase 4 study, sponsored by Charles Drew University of Medicine and Science.
- Terminated
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT00687453 is a Phase 4 study that was terminated before completion, run by Charles Drew University of Medicine and Science. The registered enrollment target is 27 participants.
The verdict
NCT00687453, a Phase 4 study, was terminated before completion, sponsored by Charles Drew University of Medicine and Science.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
To compare the efficacy and safety of once-nightly insulin glargine versus twice-daily NPH insulin in ethnic minority type 2 diabetic patients inadequately treated with once-nightly NPH insulin alone.
Interventions
- DRUG Insulin glargine at bedtime instead of NPH
- DRUG NPH twice-daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2003-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00687453
The ClinicalTrials.gov registry entry for NCT00687453 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Charles Drew University of Medicine and Science, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin glargine at bedtime instead of NPH is the first listed.
NCT00687453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00687453 about?
NCT00687453 is a clinical study titled "Insulin Glargine Versus Twice-Daily NPH". To compare the efficacy and safety of once-nightly insulin glargine versus twice-daily NPH insulin in ethnic minority type 2 diabetic patients inadequately treated with once-nightly NPH insulin alone.
What is the current status of trial NCT00687453?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2003-02. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00687453?
The interventions under investigation include: Insulin glargine at bedtime instead of NPH (DRUG), NPH twice-daily (DRUG).
Who is sponsoring clinical trial NCT00687453?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.